Learning Objectives:

  1. List the proposed molecular targets for CBD
  2. Compare and contrast the proposed mechanism of action of CBD to “traditional” ASD’s
  3. Describe the pharmacokinetics and drug interactions for CBD
  4. Discuss the most frequently encountered adverse effects of CBD in patients with LGS and Dravet
Session date: 
Monday, November 12, 2018 - 4:00pm to 5:00pm
Location: 
1220 Medical Foundation Centennial Building
1685 Highland Ave
Madison, WI 53705
United States
Presenter(s): 
Barry Gidal, PharmD, RPh
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 University of Wisconsin–Madison Continuing Education Hours

Please login or register to take this course.